Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broyl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Gerard M.J. Bos, Ka Lung Wu, Jolanda Droogendijk, Monique C. Minnema, Mario Boccadoro

Blood (2021) 138 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2021-149423

Published: 2021

Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137575

Published: 2020

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD, Michele Cavo, MD, Kazem Nasserinejad, PhD, Rosella Troia, Ludek Pour, MD, Sandra Croockewit, MD, Paolo Corradini, MD, Francesca Patriarca, MD, Kalung Wu, MD, Jolanda Droogendijk, MD, Annemiek Broyl, MD PhD, Monique C Minnema, MD PhD, Bruno Costa, Karim Saad Iskander, MD, Mario Boccadoro, MD

Blood (2018) 132 (Supplement 1): 801.

https://doi.org/10.1182/blood-2018-99-114029

Published: 2018

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Blood (2016) 128 (22): 242.

https://doi.org/10.1182/blood.V128.22.242.242

Published: 2016

Journal Articles

Superior Identification of Prognostic Relevant Copy Number Abnormalities By SNP-Based Genomic Arrays As Compared to Interphase FISH in Multiple Myeloma

Marian Stevens-Kroef, PhD, Daniel Olde Weghuis, Simone Wezenberg, Sandra Croockewit, Hans Wessels, Marjolein van der Mespel, Sonja Zweegman, MD PhD, Pino J. Poddighe, PhD

Blood (2016) 128 (22): 4426.

https://doi.org/10.1182/blood.V128.22.4426.4426

Published: 2016

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Nory Holle, Ping Wu, MBBS, MSc, Charlotte Pawlyn, MD, Radovan Saso, MD, MPhil, PhD, Jennifer G. Treleaven, MD, Michael Potter, MD PhD, Mark E Ethell, MD, Bronwen E. Shaw, MD PhD, Walter M Gregory, PhD, Sandra Croockewit, MD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 3125.

https://doi.org/10.1182/blood.V120.21.3125.3125

Published: 2012

Journal Articles

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

Blood (2012) 120 (13): 2700–2703.

https://doi.org/10.1182/blood-2012-05-430140

Published: 2012

Journal Articles

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2010) 116 (21): 40.

https://doi.org/10.1182/blood.V116.21.40.40

Published: 2010

Journal Articles

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

Blood (2010) 116 (21): 2396.

https://doi.org/10.1182/blood.V116.21.2396.2396

Published: 2010

Journal Articles

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Blood (2010) 115 (6): 1113–1120.

https://doi.org/10.1182/blood-2009-05-222539

Published: 2010

Journal Articles

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Gerard M.J. Bos, MD, PhD, Sandra Croockewit, MD, PhD, Jan J. Cornelissen, MD, PhD, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, MD, PhD, Michel Delforge, MD, PhD, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, MD, PhD, Edo Vellenga, MD, PhD, Asiong Jie, Henriette Berenschot, MD, PhD, Marinus Marwijk-kooy, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2008) 112 (11): 157.

https://doi.org/10.1182/blood.V112.11.157.157

Published: 2008

Journal Articles

High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON)

Bouke P.C. Hazenberg, MD, PhD, Sandra Croockewit, MD, PhD, Ron van der Holt, MD, PhD, Sonja Zweegman, MD, PhD, Gerard Bos, MD, PhD, Peter Vandenberghe, MD, PhD, Pieter Sonneveld, MD, PhD, Jan J. Cornelissen, MD, PhD, Edo Vellenga, MD, PhD, Pierre W. Wijermans, MD, PhD, Roelof Willemze, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Okke de Weerdt, Fokje M. Spoelstra, PhD, Henk Lokhorst, MD, PhD

Blood (2008) 112 (11): 163.

https://doi.org/10.1182/blood.V112.11.163.163

Published: 2008

Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Pieter Sonneveld, MD, Bronno van der Holt, MSc, Edo Vellenga, MD, Sandra Croockewit, MD, Gregor Verhoef, MD, Christine Segeren, MD, Henk Lokhorst, MD

Blood (2005) 106 (11): 2545.

https://doi.org/10.1182/blood.V106.11.2545.2545

Published: 2005

NARROW

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Superior Identification of Prognostic Relevant Copy Number Abnormalities By SNP-Based Genomic Arrays As Compared to Interphase FISH in Multiple Myeloma

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON)

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only